Plasma Cholesterol-Induced Lesion Networks Activated before Regression of Early, Mature, and Advanced Atherosclerosis

PLoS Genetics

Volumn 10, Issue 2, 2014, Pages

  Björkegren, Johan L M ^a,b,c   Hägg, Sara ^a,d   Talukdar, Husain A ^a   Foroughi Asl, Hassan ^a   Jain, Rajeev K ^b   Cedergren, Cecilia ^a   Shang, Ming Mei ^a   Rossignoli, Aránzazu ^a   Takolander, Rabbe ^a   Melander, Olle ^e   Hamsten, Anders ^a   Michoel, Tom ^f,g   Skogsberg, Josefin ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF TARTU   (Estonia)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UPPSALA UNIVERSITY   (Sweden)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CHOLESTEROL ESTER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; APOLIPOPROTEIN B; HISTONE LYSINE METHYLTRANSFERASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MLL5 PROTEIN, MOUSE; NUCLEAR PROTEIN; RIBONUCLEOPROTEIN; SFRS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE COURSE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE INTERACTION; GENE REGULATORY NETWORK; HUMAN; HUMAN CELL; MLL5 GENE; MOUSE; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA GEME; SRSF10 GENE; TRANSCRIPTION REGULATION; XRN2 GENE; ANIMAL; AORTA; BIOSYNTHESIS; BLOOD; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; AORTA; APOLIPOPROTEINS B; ATHEROSCLEROSIS; CHOLESTEROL; GENE EXPRESSION REGULATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, TRANSGENIC; NUCLEAR PROTEINS; RECEPTORS, LDL; RIBONUCLEOPROTEINS;

EID: 84901731028     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004201     Document Type: Article

References (60)

1. Global Atlas on Cardiovascular Disease Prevention and Control (Mendis S, Puska P, Norrving B, eds). Geneva: World Health Organization, 2011.
2. Brown MS, Goldstein JL, (2006) Biomedicine. Lowering LDL-not only how low, but how long? Science 311: 1721-1723.
3. Brown BG, Zhao XQ, Sacco DE, Albers JJ, (1993) Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87: 1781-1791.
4. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425-1435.
5. Ong HT, (2005) The statin studies: from targeting hypercholesterolaemia to targeting the high-risk patient. QJM 98: 599-614.
6. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, et al. (2006) Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 295: 1556-1565.
7. Crouse JR 3rd, Raichlen JS, Riley WA, Evans GW, Palmer MK, et al. (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297: 1344-1353.
8. Grines CL, (2006) Transcatheter cardiovascular therapeutics annual meeting. J Interv Cardiol 19: 183-210.
9. Chan AW, Bhatt DL, Chew DP, Quinn MJ, Moliterno DJ, et al. (2002) Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 105: 691-696.
10. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, et al. (2011) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev pp. CD004816.
11. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, et al. (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 1: CD004816.
12. Skogsberg J, Lundstrom J, Kovacs A, Nilsson R, Noori P, et al. (2008) Transcriptional profiling uncovers a network of cholesterol-responsive atherosclerosis target genes. PLoS Genet 4: e1000036.
13. Feig JE, Pineda-Torra I, Sanson M, Bradley MN, Vengrenyuk Y, et al. (2010) LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression. J Clin Invest 120: 4415-4424.
14. Reis ED, Li J, Fayad ZA, Rong JX, Hansoty D, et al. (2001) Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J Vasc Surg 34: 541-547.
15. Trogan E, Fayad ZA, Itskovich VV, Aguinaldo JG, Mani V, et al. (2004) Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia. Arterioscler Thromb Vasc Biol 24: 1714-1719.
16. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, et al. (2006) Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl Acad Sci U S A 103: 3781-3786.
17. Feig JE, Vengrenyuk Y, Reiser V, Wu C, Statnikov A, et al. (2012) Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome. PLoS One 7: e39790.
18. Llodra J, Angeli V, Liu J, Trogan E, Fisher EA, et al. (2004) Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc Natl Acad Sci U S A 101: 11779-11784.
19. Potteaux S, Gautier EL, Hutchison SB, van Rooijen N, Rader DJ, et al. (2011) Suppressed monocyte recruitment drives macrophage removal from atherosclerotic plaques of Apoe-/- mice during disease regression. J Clin Invest 121: 2025-2036.
20. Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, et al. (2013) Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis 227: 125-129.
21. Feig JE, Parathath S, Rong JX, Mick SL, Vengrenyuk Y, et al. (2011) Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques. Circulation 123: 989-998.
22. Lieu HD, Withycombe SK, Walker Q, Rong JX, Walzem RL, et al. (2003) Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation 107: 1315-1321.
23. Parathath S, Grauer L, Huang LS, Sanson M, Distel E, et al. (2011) Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes 60: 1759-1769.
24. Schadt EE, (2009) Molecular networks as sensors and drivers of common human diseases. Nature 461: 218-223.
25. Schadt EE, Bjorkegren JL, (2012) NEW: network-enabled wisdom in biology, medicine, and health care. Sci Transl Med 4: 115rv111.
26. Raabe M, Veniant MM, Sullivan MA, Zlot CH, Bjorkegren J, et al. (1999) Analysis of the role of microsomal triglyceride transfer protein in the liver of tissue-specific knockout mice. J Clin Invest 103: 1287-1298.
27. Ni W, Egashira K, Kitamoto S, Kataoka C, Koyanagi M, et al. (2001) New anti-monocyte chemoattractant protein-1 gene therapy attenuates atherosclerosis in apolipoprotein E-knockout mice. Circulation 103: 2096-2101.
28. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, et al. (2009) Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 41: 334-341.
29. Hagg S, Skogsberg J, Lundstrom J, Noori P, Nilsson R, et al. (2009) Multi-organ expression profiling uncovers a gene module in coronary artery disease involving transendothelial migration of leukocytes and LIM domain binding 2: the Stockholm Atherosclerosis Gene Expression (STAGE) study. PLoS Genet 5: e1000754.
30. Ramensky V, Bork P, Sunyaev S, (2002) Human non-synonymous SNPs: server and survey. Nucleic Acids Res 30: 3894-3900.
31. Holdt LM, Teupser D, (2013) From genotype to phenotype in human atherosclerosis-recent findings. Curr Opin Lipidol 24: 410-418.
32. Roberts R, Stewart AF, (2012) Genes and coronary artery disease: where are we? J Am Coll Cardiol 60: 1715-1721.
33. Feig JE, Shang Y, Rotllan N, Vengrenyuk Y, Wu C, et al. (2011) Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages. PLoS One 6: e28534.
34. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, et al. (2013) Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 19: 1166-1172.
35. Grundy SM, (1986) Cholesterol and coronary heart disease. A new era. JAMA 256: 2849-2858.
36. Bentzon JF, Falk E, (2010) Atherosclerotic lesions in mouse and man: is it the same disease? Curr Opin Lipidol 21: 434-440.
37. Goldbourt U, Yaari S, Medalie JH, (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17: 107-113.
38. Gordon DJ, Rifkind BM, (1989) High-density lipoprotein-the clinical implications of recent studies. N Engl J Med 321: 1311-1316.
39. Shah PK, Yano J, Reyes O, Chyu KY, Kaul S, et al. (2001) High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 103: 3047-3050.
40. Li R, Chao H, Ko KW, Cormier S, Dieker C, et al. (2011) Gene therapy targeting LDL cholesterol but not HDL cholesterol induces regression of advanced atherosclerosis in a mouse model of familial hypercholesterolemia. J Genet Syndr Gene Ther 2: 106.
41. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, et al. (1999) Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 100: 1816-1822.
42. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B, (2011) Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med (Berl) 89: 555-567.
43. Feig JE, Rong JX, Shamir R, Sanson M, Vengrenyuk Y, et al. (2011) HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells. Proc Natl Acad Sci U S A 108: 7166-7171.
44. Gomez D, Owens GK, (2012) Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 95: 156-164.
45. Tegner J, Skogsberg J, Bjorkegren J, (2007) Thematic review series: systems biology approaches to metabolic and cardiovascular disorders. Multi-organ whole-genome measurements and reverse engineering to uncover gene networks underlying complex traits. J Lipid Res 48: 267-277.
46. Veniant MM, Sullivan MA, Kim SK, Ambroziak P, Chu A, et al. (2000) Defining the atherogenicity of large and small lipoproteins containing apolipoprotein B100. J Clin Invest 106: 1501-1510.
47. Stotz E, Schenk EA, Churukian C, Willis C, (1986) Oil red O: comparison of staining quality and chemical components as determined by thin layer chromatography. Stain Technol 61: 187-190.
48. Wagsater D, Zhu C, Bjorkegren J, Skogsberg J, Eriksson P, (2011) MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100 mouse. Int J Mol Med 28: 247-253.
49. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, et al. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
50. Efron B, Tibshirani R, Storey J, Tusher V, (2001) Empirical Bayes analysis of a microarray experiment. J Am Stat Assoc 96: 1151-1160.
51. Pawitan Y, Michiels S, Koscielny S, Gusnanto A, Ploner A, (2005) False discovery rate, sensitivity and sample size for microarray studies. Bioinformatics 21: 3017-3024.
52. Huang da W, Sherman BT, Lempicki RA, (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57.
53. Huang da W, Sherman BT, Lempicki RA, (2009) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13.
54. Schadt EE, Molony C, Chudin E, Hao K, Yang X, et al. (2008) Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6: e107.
55. Faith JJ, Hayete B, Thaden JT, Mogno I, Wierzbowski J, et al. (2007) Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol 5: e8.
56. Madar A, Greenfield A, Vanden-Eijnden E, Bonneau R, (2010) DREAM3: network inference using dynamic context likelihood of relatedness and the inferelator. PLoS One 5: e9803.
57. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498-2504.
58. Basu SK, Goldstein JL, Anderson GW, Brown MS, (1976) Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A 73: 3178-3182.
59. Redgrave TG, Carlson LA, (1979) Changes in plasma very low density and low density lipoprotein content, composition, and size after a fatty meal in normo- and hypertriglyceridemic man. J Lipid Res 20: 217-229.
60. Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, et al. (2006) Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 47: 1833-1843.